Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM03 extension study in moderate-to-severe active rheumatoid arthritis
CTR20220757Phase 3Active
- Sponsor
- Longrui Pharmaceutical
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of suciraslimab in rheumatoid arthritis (RA), sponsored by Longrui Pharmaceutical. Started Jul 2022; status: active.
02
Drugs
suciraslimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20220757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220757.